Acadia Pharmaceuticals | ACAD - Pre Tax Profit



Acadia Pharmaceuticals reported $40.21M in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 40.21M 12.43M Jun/2025
ALKERMES USD 104.84M 79.35M Jun/2025
Alnylam Pharmaceuticals USD -35358000 6.24M Jun/2025
Biogen USD 744M 432.8M Jun/2025
BioMarin Pharmaceutical USD 297.87M 59.78M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Corcept Therapeutics USD 31.69M 22.07M Jun/2025
Cytokinetics USD -134370000 27.01M Jun/2025
Eisai JPY 22.4B 22.43B Jun/2025
Eli Lilly USD 6.78B 3.32B Jun/2025
Incyte USD 558.01M 323.82M Jun/2025
J&J USD 13.63B 8.21B Mar/2025
Moderna USD -818000000 146M Jun/2025
Neurocrine Biosciences USD 159.5M 144.8M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
Prothena USD -80960000 21.46M Jun/2025
PTC Therapeutics USD -71052000 1B Jun/2025
Sarepta Therapeutics USD 153.64M 537.16M Jun/2025
Ultragenyx Pharmaceutical USD -114004000 35.77M Jun/2025
Vertex Pharmaceuticals USD 1.28B 552.6M Jun/2025